Oric Pharmaceuticals
Jian Wang has a strong background in data sciences and biostatistics, with extensive experience in various roles. Jian is currently serving as the Director of Data Sciences at ORIC Pharmaceuticals Inc. Prior to this, they worked as the Director of Biostatistics and Data Management at Caladrius Biosciences, Inc. from 2019 to 2022. Before that, Jian held the position of Director of Biostatistics - BDM at Cytel from 2017 to 2019. Jian also worked at Takeda as a Principal Statistician from 2014 to 2017, and as a Senior Statistician from 2011 to 2014. Jian's earlier experience includes roles as a Senior Biostatistician and Biostatistician at Regeneron Pharmaceuticals, Inc., a Biostatistician at Columbia University, and a Research Analyst at the University of Maryland Baltimore County.
Jian Wang started their education at Peking University Health Science Center in 1993, where they received their M.D. degree in an unspecified field of study in 1998. Following this, from 1998 to 2001, they pursued a Master of Science degree in Physiology at the same institution. In 2001, Jian Wang enrolled at The Johns Hopkins University and completed their Master of Science degree in Biostatistics in 2003.
This person is not in any offices
Oric Pharmaceuticals
ORIC Pharmaceuticals is a privately held, clinical-stage oncology company focused on making cancer treatments more effective by addressing mechanisms of resistance. ORIC's lead asset, ORIC-101, is a potent and selective small-molecule antagonist of the glucocorticoid receptor. ORIC's pipeline targets other undisclosed mechanisms of oncology therapy resistance. ORIC's scientific founders are Drs. Charles Sawyers, MD, and Scott Lowe, PhD, who have strong records of discovering innovative treatments and targets in cancer. The company has assembled strong leadership and scientific teams and a board with extensive experience in drug development and financing. ORIC is funded by leading biotechnology investors, including The Column Group, Topspin Partners, OrbiMed Advisors, EcoR1 Capital, Fidelity Management & Research Company, Trinitas Capital, Foresite Capital, Taiho Ventures, Memorial Sloan Kettering, Kravis Investment Partners, NS Investment and City Hill Ventures. ORIC is headquartered in South San Francisco, California.